Akebia Therapeutics (AKBA) Projected to Announce Earnings on Wednesday

Akebia Therapeutics (NASDAQ:AKBA) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Akebia Therapeutics to post earnings of ($0.03) per share and revenue of $48.8520 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). The company had revenue of $53.54 million for the quarter, compared to analysts’ expectations of $51.67 million. Akebia Therapeutics had a negative return on equity of 62.72% and a negative net margin of 8.83%. On average, analysts expect Akebia Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Akebia Therapeutics Stock Performance

Shares of AKBA stock opened at $1.31 on Tuesday. The firm’s 50-day simple moving average is $1.16 and its two-hundred day simple moving average is $1.27. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.33 and a current ratio of 1.40. Akebia Therapeutics has a 52 week low of $0.82 and a 52 week high of $3.79. The firm has a market cap of $351.42 million, a price-to-earnings ratio of -16.38 and a beta of 0.26.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on AKBA shares. Zacks Research raised Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Akebia Therapeutics in a research note on Wednesday, May 6th. Wall Street Zen downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. BTIG Research reiterated a “buy” rating and set a $4.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, April 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Akebia Therapeutics in a report on Wednesday, July 1st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.67.

Insider Buying and Selling

In related news, CFO Erik Ostrowski sold 56,019 shares of Akebia Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $1.11, for a total value of $62,181.09. Following the completion of the transaction, the chief financial officer directly owned 616,616 shares in the company, valued at approximately $684,443.76. The trade was a 8.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Akebia Therapeutics

Large investors have recently made changes to their positions in the stock. Cibc World Markets Corp bought a new stake in shares of Akebia Therapeutics during the 4th quarter valued at $27,000. Caption Management LLC bought a new stake in shares of Akebia Therapeutics during the fourth quarter valued at about $40,000. Baird Financial Group Inc. lifted its holdings in shares of Akebia Therapeutics by 23.0% in the first quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,000 shares in the last quarter. Polymer Capital Management US LLC lifted its holdings in shares of Akebia Therapeutics by 49.5% in the third quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 6,034 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in shares of Akebia Therapeutics in the second quarter valued at approximately $62,000. 33.92% of the stock is owned by institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.